Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

12.4K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
12.4K
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

660
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
660
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

10.6K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
10.6K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

2.0K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.0K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

4.8K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
4.8K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

4.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Miroslav Z. Papiz (1955-2026).

Acta crystallographica. Section D, Structural biology·2026
Same author

Crystallography in Open Science and its open educational resources.

Acta crystallographica. Section A, Foundations and advances·2026
Same author

Guiding AlphaFold predictions with experimental knowledge to inform dynamics and interactions with VAIRO.

Protein science : a publication of the Protein Society·2026
Same author

50th anniversary of the Stanford SSRL synchrotron radiation and protein crystallography initiative.

Journal of synchrotron radiation·2026
Same author

Macromolecular crystallography for mammalian body temperature in support of molecular biophysics methods.

Biophysical reviews·2025
Same author

Towards patient-relevant structures: reviewing body-temperature biological macromolecules and their ligands for pharmaceutical applications.

Acta crystallographica. Section D, Structural biology·2025

Related Experiment Video

Updated: Apr 24, 2026

In Vitro Characterization of Histone Chaperones using Analytical, Pull-Down and Chaperoning Assays
08:16

In Vitro Characterization of Histone Chaperones using Analytical, Pull-Down and Chaperoning Assays

Published on: December 29, 2021

2.5K

Carboplatin binding to histidine.

Simon W M Tanley1, Kay Diederichs2, Loes M J Kroon-Batenburg3

  • 1School of Chemistry, Faculty of Engineering and Physical Sciences, University of Manchester, Brunswick Street, Manchester M13 9PL, England.

Acta Crystallographica. Section F, Structural Biology Communications
|September 9, 2014
PubMed
Summary
This summary is machine-generated.

This study investigated carboplatin

Keywords:
NaBr crystallization conditionsavoid partial conversion to cisplatincarboplatinhistidinemodel protein (hen egg-white lysozyme)non-NaCl crystallization conditions

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

12.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K

Related Experiment Videos

Last Updated: Apr 24, 2026

In Vitro Characterization of Histone Chaperones using Analytical, Pull-Down and Chaperoning Assays
08:16

In Vitro Characterization of Histone Chaperones using Analytical, Pull-Down and Chaperoning Assays

Published on: December 29, 2021

2.5K
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

12.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K

Area of Science:

  • Biochemistry
  • Crystallography
  • Pharmacology

Background:

  • Carboplatin is a platinum-based chemotherapy drug.
  • Previous studies showed carboplatin converts to cisplatin under high NaCl conditions.
  • The binding of carboplatin to histidine in hen egg-white lysozyme (HEWL) is not fully understood.

Purpose of the Study:

  • To investigate carboplatin binding to HEWL under varying conditions.
  • To determine if carboplatin converts to a bromine form in NaBr.
  • To resolve the crystal structure of carboplatin bound to histidine without chemical conversion.

Main Methods:

  • Co-crystallization of HEWL with carboplatin.
  • X-ray crystallography.
  • Experiments conducted in NaBr and without NaCl at various pH values.

Main Results:

  • Carboplatin partially converted to a transplatin form in NaBr.
  • Successful crystallization of HEWL with carboplatin without NaCl.
  • Carboplatin bound to His15 of HEWL, with binding mode dependent on anion concentration, time, and pH.
  • The cyclobutanedicarboxylate moiety of carboplatin was not fully resolved in the crystal structure.

Conclusions:

  • Carboplatin can undergo chemical transformation in the presence of halides.
  • Eliminating NaCl prevents carboplatin conversion, allowing study of its direct binding.
  • Understanding carboplatin's binding and potential transformations is crucial for its anticancer drug efficacy.